If you are wondering whether GSK shares still offer value at around £18.86, you are not alone. The stock has been attracting ...

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

GSK plc (NYSE:GSK) is one of the best affordable healthcare stocks to buy now. GSK plc (NYSE:GSK) announced on December 19 an agreement with the United States administration to lower the cost of ...

GSK plc (NYSE:GSK) is one of the best performing pharma stocks in 2025. Jefferies reaffirmed a Buy rating on GSK plc ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval of Nucala for chronic obstructive pulmonary disease (COPD) and a positive ...

GSK and Ionis report strong Phase 3 results for a hepatitis B drug that improved cure rates and could support regulatory filings in early 2026.

GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) ...